CORRECTION article
Front. Oncol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1682157
This article is part of the Research TopicNovel Anti-Cancer Agents Targeting Tumour Metastasis and Stemness - Volume IIView all 4 articles
Correction: Integrating network pharmacology and transcriptomics to identify solasonine’s anti-osteosarcoma targets and experimental validation
Provisionally accepted
- 1General Hospital of Ningxia Medical University, Yinchuan, China
- 2departmen of orthopedic，General hospital of ningxia medical university, Yinchuan, China
- 3Ningxia Medical University, Yinchuan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Keywords: solasonine, Osteosarcoma, Network Pharmacology, Transcriptomics, experimental validation
Received: 08 Aug 2025; Accepted: 24 Sep 2025.
Copyright: © 2025 Wei, Li, Chu and Shi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jiandang Shi, shi_jiandang@nxmu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.